Searchable abstracts of presentations at key conferences in endocrinology

ea0012p50 | Diabetes, metabolism and cardiovascular | SFE2006

Evidence for a safe switch from human premixed insulin to BIAsp 30 in twice-daily regimens – data from the REACH study

McNally PG , Page S , Compion G , Lorains J

AimsThe premixed insulin analogue, biphasic insulin aspart 30/70 (BIAsp 30, 30% insulin aspart, 70% protaminated aspart) has a more physiological absorption profile than conventional premixed insulin, biphasic human insulin 30/70 (BHI 30, 30% soluble human insulin, 70% NPH), but no studies have previously tested how a switch from BHI 30 to BIAsp 30 can be done safely using a simple guideline. We investigated the occurrence of low interstitial glucose (IG...